High-dose paclitaxel in combination with doxorubicin, cyclophosphamide and peripheral blood progenitor cell rescue in patients with high-risk primary and responding metastatic breast carcinoma: toxicity profile, relationship to paclitaxel pharmacokinetics and short-term outcome

We assessed the feasibility and pharmacokinetics of high-dose infusional paclitaxel in combination with doxorubicin, cyclophosphamide, and peripheral blood progenitor cell rescue. Between October 1995 and June 1998, 63 patients with high-risk primary [stage II with ≥ 10 axillary nodes involved, stag...

Descripción completa

Detalles Bibliográficos
Autores principales: Somlo, G, Doroshow, J H, Synold, T, Longmate, J, Reardon, D, Chow, W, Forman, S J, Leong, L A, Margolin, K A, Jr, R J Morgan, Raschko, J W, Shibata, S I, Tetef, M L, Yen, Y, Kogut, N, Schriber, J, Alvarnas, J
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2001
Materias:
Regular Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2363687/
https://www.ncbi.nlm.nih.gov/pubmed/11401310
http://dx.doi.org/10.1054/bjoc.2001.1835

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2363687/
https://www.ncbi.nlm.nih.gov/pubmed/11401310
http://dx.doi.org/10.1054/bjoc.2001.1835

Ejemplares similares